Nexentis Technologies Inc.
Close on Oct 19, 2026
- Market cap
- $522.65K
- P/E (TTM)
- –
- Dividend yield
- –
About Nexentis Technologies
Pharmaceutical Preparations, SIC 2834
Nexentis Technologies, Inc. is a corporate entity engaged in biotechnology activities and renewable energy projects. Through its operating segments, the company participates in agricultural and life science ventures, including collaborations and investments associated with Save Foods Ltd., Plantify Foods, and MitoCareX Bio Ltd. Additionally, the business focuses on clean energy initiatives through solar photovoltaic joint ventures and partnership arrangements involving Solterra Renewable Energy Ltd., serving commercial, technological, and agricultural markets.
The company maintains operational activities and jurisdictional interests across Israel, the United States, and Italy. Its primary executive offices and headquarters are located at Pinhas Sapir St. 3, Kiryat HaMada, Ness Ziona 7403626, Israel. Nexentis Technologies also holds active partnership agreements, commercial arrangements, and facility leases across these international operating regions.
Summary of the business section of Nexentis Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nexentis Technologies Inc.
- Headquarters
- New York, NY
- Address
- 156 Fifth Avenue 10th Floor, Co Earthbound Llc 10010-7751
- Phone
- 972544561349
- Employees
- 7, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Somekh Chaikin, Tel Aviv, Israel
Stock & identifiers
- Ticker
- NXTS
- Exchange
- Nasdaq
- IPO date
- May 17, 2021
- Shares outstanding
- 1M, Aug 13, 2026
- Public float
- $6.39M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-7 reverse, Apr 8, 2026; 1-for-35 reverse, Sep 22, 2025; 1-for-6.67 reverse, Nov 14, 2023; 1-for-7 reverse, Oct 6, 2023; 1-for-7 reverse, Mar 29, 2021; 1-for-7 reverse, Feb 25, 2021; 1-for-15 reverse, Jun 13, 2019
- SEC CIK
- 1789192
- CUSIP
- 80512Q600
- ISIN
- US80512Q6008
- EIN
- 26-4684680
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Shlomo Zakai | Controller | 87,000 |
| Lital Barda | Chief Financial Officer | 267,227 |
| David Palach | Chief Executive Officer | 549,144 |
| Amitay Weiss | Director | 579,144 |
| Udi Ovadia Kalifi | Director | 68,457 |
| Asaf Itzhaik | Director | 50,000 |
| Eliahou Arbib | Director | 64,500 |
| Liat Sidi | Director | 50,000 |
| Ronen Rosenbloom | Director | 64,500 |
| Israel Yakov Berenstein | Director | 64,500 |
Employees
Headcount reported in annual reports
“As of March 31, 2026, we, together with our wholly owned subsidiary, MitoCareX, have seven full-time employees and two part time employees.”
Corporate history
Events identified from SEC filings